These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2341577)

  • 1. FDA audits of clinical studies: policy and procedure.
    Lisook AB
    J Clin Pharmacol; 1990 Apr; 30(4):296-302. PubMed ID: 2341577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's conduct, review, and evaluation of inspections of clinical investigators.
    Turner G; Lisook AB; Delman DP
    Drug Inf J; 1987; 21(2):117-25. PubMed ID: 10282112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U.S. Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009.
    Morgan-Linnell SK; Stewart DJ; Kurzrock R
    Clin Cancer Res; 2014 Jul; 20(13):3364-70. PubMed ID: 24737548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
    Seife C
    JAMA Intern Med; 2015 Apr; 175(4):567-77. PubMed ID: 25664866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of data audits in detecting scientific misconduct. Results of the FDA program.
    Shapiro MF; Charrow RP
    JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
    Sellers JW; Mihaescu CM; Ayalew K; Kronstein PD; Yu B; Ning YM; Rodriguez M; Williams L; Khin NA
    Ther Innov Regul Sci; 2022 Sep; 56(5):753-764. PubMed ID: 35610469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B.
    Weiss RB; Vogelzang NJ; Peterson BA; Panasci LC; Carpenter JT; Gavigan M; Sartell K; Frei E; McIntyre OR
    JAMA; 1993 Jul; 270(4):459-64. PubMed ID: 8320783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world.
    Caldron PH; Gavrilova SI; Kropf S
    Drug Des Devel Ther; 2012; 6():53-60. PubMed ID: 22563236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent changes in quality in Japanese clinical trials.
    Saito K; Kodama Y; Ono S; Fujimura A
    Ann Pharmacother; 2004 Jan; 38(1):151-5. PubMed ID: 14742810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations.
    Garmendia CA; Epnere K; Bhansali N
    Ther Innov Regul Sci; 2018 Sep; 52(5):579-591. PubMed ID: 29714561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing oncology research protocols.
    Lunik MC
    Top Hosp Pharm Manage; 1994 Jul; 14(2):11-21. PubMed ID: 10136201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raising suspicions with the Food and Drug Administration: detecting misconduct.
    Hamrell MR
    Sci Eng Ethics; 2010 Dec; 16(4):697-704. PubMed ID: 20842536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
    Romano CA; Nair S; Delphin ES
    Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research Misconduct in FDA-Regulated Clinical Trials: A Cross-sectional Analysis of Warning Letters and Disqualification Proceedings.
    Garmendia CA; Bhansali N; Madhivanan P
    Ther Innov Regul Sci; 2018 Sep; 52(5):592-605. PubMed ID: 29714564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on the U.S. FDA Bioresearch Monitoring Program.
    Gamet JE
    Qual Assur; 1995 Mar; 4(1):12-9. PubMed ID: 8520859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.